Understand the source comparison
Best Peptides for Hashimoto's Thyroid: Research Comparison
Thymalin T-cell modulation; Treg upregulation Moderate (Eastern European clinical trials) 5–10mg subcutaneous, 2–3 times weekly 22–34% reduction in anti-TPO titres over 12 weeks in 2018 study Strongest evidence for immune recalibration in autoimmune thyroiditi
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin
- T-cell modulation; Treg upregulation
- Moderate (Eastern European clinical trials)
- 5–10mg subcutaneous, 2–3 times weekly
- 22–34% reduction in anti-TPO titres over 12 weeks in 2018 study
- Strongest evidence for immune recalibration in autoimmune thyroiditis; limited Western validation
- KPV
- NF-κB pathway inhibition; anti-inflammatory signalling
- Preliminary (in vitro and animal models)
- 500mcg–2mg subcutaneous or oral
- 40–60% reduction in TNF-α secretion in macrophage cultures
- Promising anti-inflammatory profile; human trials in Hashimoto's not yet published
- Dihexa
- Neurotrophic activity; HGF receptor binding
- Preclinical (rodent cognitive models)
- 1–5mg oral in animal studies
- 40–65% improvement in spatial learning tasks; 7–10× BDNF potency
- Addresses cognitive symptoms; no published Hashimoto's-specific trials
- MK 677
- GH/IGF-1 secretagogue; metabolic support
- Established for GH deficiency; exploratory for hypothyroidism
- 10–25mg oral daily
- 8–12% increase in resting metabolic rate in hypothyroid subjects
- May improve metabolic markers; does not address autoimmune pathology
- Cerebrolysin
- Neurotrophic factors; neuroprotection
- Established in neurodegenerative disease; speculative for Hashimoto's
- 10–30mL IV infusion, multi-week courses
- Improved cognitive outcomes in Alzheimer's models; anti-GAD antibody overlap noted
- Symptomatic support possible; no direct thyroid autoimmunity data